title: Antiproliferative activity of mammalian lignan derivatives against the human breast carcinoma cell line, ZR-75-1.
abstract: The effect of each of twelve mammalian lignan derivatives on the growth of human mammary tumor ZR-75-1 cells was examined. At a concentration less than 10 micrograms/ml, tumor cell growth was inhibited from 18-68%. The effect of 2,3-dibenzylbutane-1,4-diol(hattalin) was found to be strongest, inhibiting growth by 50% at a concentration (EC50) of 2.1 micrograms/ml. Hattalin inhibited membrane Na+, K(+)-ATPase of canine kidney cortex. It also inhibited the ATPase of the plasma membrane fraction from both cultured cells and a section of human breast cancer tissue at a concentration ranging from 0.5 to 2.0 mM. However, only a few percent of membrane ATPase from either ZR-75-1 cells or breast carcinoma tissue was inhibited by 2.0 mM of ouabain, suggesting that the target ATPase of hattalin was other than ouabain-sensitive ATPase. The relative incorporation of [3H]thymidine per 1 x 10(5) cells into the acid-precipitable fraction of ZR-75-1 cells was not affected by 1-50 micrograms/ml of hattalin, while a marked decrease resulted from 1-10 micrograms/ml of 5-fluorouracil (5-FU). These results suggest that the suppressive effect of hattalin on tumor cell growth may not occur through inhibition of DNA synthesis but rather partly by inhibition of the plasma membrane ATPase other than Na+ and K(+)-dependent ones.
authors: Division of Clinical Pharmacology, Tokyo College of Pharmacy, Japan.
authors: T
authors: T
authors: Hirano
authors: K
authors: K
authors: Fukuoka
authors: K
authors: K
authors: Oka
authors: T
authors: T
authors: Naito
authors: K
authors: K
authors: Hosaka
authors: H
authors: H
authors: Mitsuhashi
authors: Y
authors: Y
authors: Matsumoto
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives / Q000494:pharmacology; D000251:Adenosine Triphosphatases / Q000032:analysis / Q000302:isolation & purification; D000818:Animals; D001593:Benzyl Compounds / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002072:Butylene Glycols / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D007672:Kidney Cortex / Q000187:drug effects; D007928:Lethal Dose 50; D017705:Lignans; D010042:Ouabain / Q000494:pharmacology
chemical_list: D001593:Benzyl Compounds; D002072:Butylene Glycols; D017705:Lignans; C063012:2,3-dibenzylbutane-1,4-diol; D010042:Ouabain; C029498:2,3-bis(3'-hydroxybenzyl)butane-1,4-diol; D000251:Adenosine Triphosphatases; D015107:4-Butyrolactone; D005472:Fluorouracil; C029497:2,3-bis(3'-hydroxybenzyl)butyrolactone